The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

115 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-02-29

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, observational study of the volumizing effect of aesthetic use of Juvéderm VOLUMA® with lidocaine in the mid-face area.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Deficiency

NCT01029535

Mid-face Volume Deficiency

COMPLETED NA

A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment

NCT04927052

Volume Deficit in the Mid-face

COMPLETED NA

An Interventional Study to Evaluate the Safety and Performance of Crosslinked Hyaluronic Acid Hydrogel

NCT05853224

Dermal Filler Volume Deficiency of the Midface

UNKNOWN NA

Efficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit

NCT07162610

Mid-face Volume Deficit

ACTIVE_NOT_RECRUITING NA

Clinical Investigation for Evaluating the Safety and Efficacy of JTM102 to Mid Face Volume Deficiency

NCT07265778

Mid Face Volume Deficit

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-related Volume Deficit in the Mid-face

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Age group A

Subjects 30 to 40 years old

Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)

Intervention Type DEVICE

All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.

Age group B

Subjects 40 to 50 years old

Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)

Intervention Type DEVICE

All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.

Age group C

Subjects over 50 years old

Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)

Intervention Type DEVICE

All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)

All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Juvéderm VOLUMA® with lidocaine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Desire and willingness for correction of asymmetry or enhancement of his/her mid-face area.
* Be willing to undergo treatment for volume loss in the face area
* Females and males ≥30 years of age
* Be in good health as of the opinion of the Investigator
* Sign the Informed Consent Form prior to any study-related procedures being performed
* Have established a realistic treatment goal that the Investigator agrees is achievable i.e., have realistic expectations of aesthetic results

Exclusion Criteria

* Have extensive tissue damage that could affect the aesthetic outcome
* Have a known allergy to any component of VOLUMA® with lidocaine injections
* Have an abscess or infection at the time of treatment that in the opinion of the Investigator does not make the subject eligible for the procedure.
* Have undergone cosmetic facial \[e.g., face-lift, or other surgeries, which may alter the appearance of the mid-face region (laser, photomodulation intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, or other ablative procedures), tissue augmentation with dermal fillers or fat injections, or meso-therapy\] anywhere in the mid-face region, or Botox® Cosmetic injections in the lower face (below the orbital rim), within the 6 months prior to entry in the study or be planning to undergo any of these procedures at any time during the study. NOTE: Prior treatment with hyaluronic acid (HA) fillers and/or collagen is allowed, provided the treatment was administered more than 6 months prior to study entry
* Have ever received semi-permanent fillers or permanent facial implants, e.g., calcium hydroxyapatite, L-polylactic acid, polymethylmethacrylate (PMMA), silicone, expanded polytetrafluoroethylene (ePTFE) anywhere in the lips, or be planning to be implanted with any of these products at any time during the study
* Have a history of anaphylaxis, multiple severe allergies, atopy, allergy to lidocaine (or any amide-based anesthetics), HA products, or Streptococcal protein, or be planning to undergo a desensitization therapy during the term of the study
* Suffer from an uncontrolled personality disorder (e.g., body dysmorphia, depression)
* Have a history of or currently suffer from an autoimmune disease (e.g., Rheumatoid arthritis, Crohn's disease)
* Have a history of streptococcal disease (e.g., strep throat or rheumatic fever with or without heart complications)
* Have a history of skin cancer
* Suffer from Porphyria
* Have epilepsy which is not controlled by anti-epilepsy therapy
* Current cutaneous inflammatory and/or infectious processes (e.g., acne, herpes, etc.)
* Have a history of treatment with interferon therapy (e.g., warfarin) or have taken non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen) or other substances known to increase coagulation time (e.g., herbal supplements with garlic or ginko biloba) within 10 days of undergoing study device injection. NOTE: Study device injection may be delayed as necessary to accommodate this 10-day washout period
* Be on a concurrent regimen of high doses of lidocaine (more than 400 mg) which may cause acute toxic reactions
* Be on a concurrent regimen of other local anesthetics structurally related to amide-type local anesthetics
* Have impaired cardiac conduction, severly impaired hepatic function, or severe renal dysfunction
* Have a condition or be in a situation that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes